Navigation Links
Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months
Date:10/5/2007

long-term coadministration study planned for patients with routine high cholesterol, both expected to begin this year, Isis has selected 200 mg/week as its development dose.

About Familial Hypercholesterolemia

Familial hypercholesterolemia is a genetic condition that results in markedly elevated LDL-C levels beginning at birth and heart attacks at an early age. People with the disease have consistently high levels of LDL-C, which leads to premature atherosclerosis of the coronary arteries. Current therapies for FH are inadequate, and the most severely affected patients may need apheresis, an expensive and time-consuming procedure that removes the "bad" cholesterol from the blood. Homozygous FH is rare, affecting about one in one million people, but heterozygous FH is much more common with a prevalence of approximately one in every 500 people.

Conference Call Information

At 8:00 a.m. Eastern Time Monday, October 8, Isis will conduct a live webcast conference call to discuss ISIS 301012 results. Interested parties may access the webcast at http://www.isispharm.com or listen to the call by dialing 888-211-7384 (U.S.) / 913-312-0380 (International). A replay will be available for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclus
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... The world is at a "hinge ... to create new opportunities for leadership in health ... WesternU's 34th annual Commencement Exercises said Wednesday, May ... former San Francisco mayor and likely 2018 gubernatorial ... ceremony for WesternU's colleges of Allied Health Professions ...
(Date:5/22/2015)... The American College of Traditional Chinese Medicine ... will hold a webinar on the updates of the ... Classical Chinese Medicine. , Webinar – First Professional Doctorate ... Dean of Clinical Education, will lead this webinar in ... program. ACTCM is currently developing this degree program based ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board ... system’s Chief Financial Officer (CFO), will be leaving the ... the company CFO since 2011. , The Board of ... health system as CFO. Wesley will oversee the health ... Board of Trustees conducts a formal search for a ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health Limited ... brand Nature’s Way, Marc St-Onge has affirmed his commitment ... is an integral part of the agreement with Nature’s ... further develop Ascenta Skin into a leading player in ... breakthrough, anti-aging skincare supplement featuring 6 active ingredients including ...
(Date:5/22/2015)... UK (PRWEB) May 22, 2015 ... leading treatment option for chronic obstructive pulmonary disorder ... GlaxoSmithKline plc and AstraZeneca plc as well as ... market share and position. But will market payers, ... the already well-entrenched products to completely new ones? ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
... Pa., Oct. 31 After already launching three,well-received ... the newest additions to its healthy snacks available ... to fit their own style,and schedule. Continuing their ... added two new options with a variety of ...
... (+44% y/y) - 2008 EPS Guidance Increased ... - ... HMS Holdings Corp. (Nasdaq:,HMSY) today announced its financial results for the third ... September 30, 2008 revenue increased 30% to $49.0,million, compared with $37.7 million ...
... 2.0 tools by suppliers in the senior care marketplace? Are print advertising ... are answered in our latest “Trends in Senior Care Marketing" report. ... ... use of blogs, podcasts and other Web 2.0 tools by suppliers in ...
... coma, 6 year chronic sciatica back pain, 15- and 25-year ... these conditions were overcome using advanced magnetic therapy techniques developed ... ... (PRWEB) October 31, 2008 -- Regenerating nerves, waking people from ...
... should not give up and start over after they,ve been denied disability ... ... Belleville, Ill. (Vocus) October 31, 2008 -- Getting a denial letter after ... leads some people to call it quits, according to Allsup , ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) management will present at ... at 8:00 AM at,the Waldorf-Astoria Hotel., The conference will also ... The webcast can be accessed at, http://www.celltherapeutics.com ., ... 19th Annual Healthcare Conference ...
Cached Medicine News:Health News:Lifestyle Foods Introduces Two New Healthy Snack Options 2Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 2Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 3Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 4Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 5Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 6Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 7Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 8Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 9Health News:HMS Holdings Corp. Announces Q3 2008 Results, 2008 Revised Guidance and Initial 2009 Guidance 10Health News:Complimentary White Paper: Where Senior Care Suppliers Spent Marketing and PR Dollars in 2007 and 2008 2Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 2Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 3Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 4Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 5Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 2Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 3Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 4Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 5Health News:Beware of Ten Mistakes after Social Security Denies Disability Benefits 6
(Date:5/22/2015)...  BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading ... storage and cryopreservation freeze media and ... or the "Company"), announced that the Company is scheduled to ... The Company is scheduled to present at the Conference at ... Grand Hyatt Hotel in New York City ...
(Date:5/22/2015)... , May 22, 2015 The ... the $13 billion global cardiac rhythm management device ... Kalorama found that Medtronic, St. Jude Medical, Boston ... 80% of this market segment. The healthcare market ... Markets , uses 2015 as a base year, ...
(Date:5/22/2015)... , May 22, 2015  The U.S. Food ... (filgrastim-sndz) -- the first biosimilar product approved in ... points toward growth in the contract manufacturing organization ... CMO industry is geared to the production of ... major biopharmaceutical products. The healthcare market research publisher,s ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... THE WOODLANDS, Texas, Sept. 30, 2011 David, a ... grandfather, felt too young to be diagnosed with prostate ... symptoms." David, under the advisement of his oncologist, decided ... first in a new therapeutic class known as autologous ...
... 30, 2011 The CyberKnife Coalition announced ... CyberKnife Robotic Radiosurgery System® have now been enrolled in ... prostate cancer patients treated with stereotactic body ... (RPCR), tracks clinical and functional outcomes of men with ...
Cached Medicine Technology:The US Oncology Network Affiliated Physicians at Forefront of Cutting-Edge Prostate Cancer Treatment 2The US Oncology Network Affiliated Physicians at Forefront of Cutting-Edge Prostate Cancer Treatment 3The US Oncology Network Affiliated Physicians at Forefront of Cutting-Edge Prostate Cancer Treatment 4First Prostate Cancer Registry for Robotic Radiosurgery Patients Enrolls More than 500 Men 2
... Screening (HTS), Analyst HT smoothes the ... sharing all the detection modalities and ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ... into robotic environments, including those from ...
... all the right features for assay ... simple instrument control. Reduces the inevitable ... into HTS. Specifically developed to meet ... Analyst AD delivers unparalleled detection performance ...
... FLUOstar is a flexible multifunction plate reader ... one instrument: fluorescence intensity, time-resolved fluorescence, high-perfomance ... be equipped with injectors that deliver reagent ... fast kinetic cell assays can be performed ...
This new dedicated VICTOR2 model is for fluorescence and luminescence measurements....
Medicine Products: